Copyright
©The Author(s) 2017.
World J Gastroenterol. Dec 21, 2017; 23(47): 8355-8366
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8355
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8355
Figure 4 Effect of rifaximin on endotoxin activity.
Comparison of the endotoxin activities between baseline and 4 wk post-rifaximin among (A) total patients (n = 20) and (B) the patients who showed high levels of EA (> 0.4) at baseline (n = 11). C: Univariate correlation analysis between the decrease in EA level (Δ EA) and that in serum ammonia level (Δ NH3) by treatment with rifaximin (r = 0.5886, P < 0.05). Data are means ± SD.
- Citation: Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol 2017; 23(47): 8355-8366
- URL: https://www.wjgnet.com/1007-9327/full/v23/i47/8355.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i47.8355